Datasheet

Bcl9L Antibody
CATALOG NUMBER: 6213

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Mouse: (100%), Rat: (100%)
TESTED APPLICATIONS:ELISA, ICC, IF, IHC-P, WB
APPLICATIONS:Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL and immunocytochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1201 - HeLa Cell Lysate
 2) Cat. No. 17-001 - HeLa Cell Slide
PREDICTED MOLECULAR WEIGHT:Predicted: 165 kDa

Observed: 195 kDa
SPECIFICITY:Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.
IMMUNOGEN:Bcl9L antibody was raised against a 20 amino acid synthetic peptide near the amino terminus of human Bcl9L.

The immunogen is located within amino acids 20 - 70 of Bcl9L.
HOST SPECIES:Rabbit

Properties

PURIFICATION:Bcl9L Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:Bcl9L Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:Bcl9L antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:Bcl9L Antibody: BCL9-2, DLNB11, Protein BCL9-2, B-cell lymphoma 9-like protein
ACCESSION NO.:NP_872363
PROTEIN GI NO.:32698936
OFFICIAL SYMBOL:BCL9L
GENE ID:283149

Background

BACKGROUND:Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.
REFERENCES: 1) Katoh M and Katoh M. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. Int. J. Mol. Med. 2003; 12:643-9.
2) Adachi S, Jigami T, Yasui T, et al. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res. 2004; 64:8496-501.
3) Toya H, Oyama T, Ohwada S, et al. Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers. Cancer Sci. 2007; 98:484-90.
4) Deka J, Wiedemann N, Anderle P, et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinoma. Cancer Res. 2010; 70:6619-28.

For Research Use Only